<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05067894</url>
  </required_header>
  <id_info>
    <org_study_id>CoV2-010221</org_study_id>
    <nct_id>NCT05067894</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine</brief_title>
  <official_title>A Phase I/II, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Populations Aged 18 Years and Above in Indonesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fakultas Kedokteran Universitas Indonesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Health Research and Development, Ministry of Health Republic of Indonesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an observer-blind, randomized, controlled prospective intervention study of&#xD;
      Phase I/II. The primary objective of Phase I is To evaluate the safety of the SARS-CoV-2&#xD;
      protein subunit recombinant vaccine within 7 days after each dose. Whereas, the primary&#xD;
      objective of Phase II is to evaluate the immunogenicity profile of the SARS-CoV-2 protein&#xD;
      subunit recombinant vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is observer blinded, comparative, randomized, phase I/II study. For phase I,&#xD;
      approximately 90 subjects will be recruited and will seamlessly continue to phase II&#xD;
      recruiting 690 subjects, in total 780 subjects (18 years and above).&#xD;
&#xD;
      Two different formulations of vaccine candidate (SARS-CoV-2 protein subunit recombinant&#xD;
      vaccine) will be compared to active control. The investigational product is 0.5 ml in three&#xD;
      dose-regimen (for all subjects) with 28 days apart between doses. Antibody testing after two&#xD;
      doses will be conducted to compare the immunogenicity profile between two and three-dose&#xD;
      administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Observer blind: Investigational Product and Active Comparator are masking. Lot number is masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I Safety of the SARS-CoV-2 protein subunit recombinant vaccine within 7 days after each dose</measure>
    <time_frame>7 days after each dose</time_frame>
    <description>percentage of subjects with solicited and unsolicited Adverse Events (AE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II Immunogenicity profile of the SARS-CoV-2 protein subunit recombinant vaccine after whole schedule dose</measure>
    <time_frame>28 days after third dose</time_frame>
    <description>percentage of subjects with seropositive, seroconversion and Geometric Mean Ration (GMT) of Immunoglobulin (IgG) antibody and Neutralization antibody</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety of the SARS-CoV-2 protein subunit recombinant vaccine within 28 days after each dose</measure>
    <time_frame>28 days after each dose</time_frame>
    <description>percentage of subjects with solicited and unsolicited AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of AE/ Serious Adverse Events (SAE) between intervention vaccine and active control</measure>
    <time_frame>28 days after each dose</time_frame>
    <description>percentage of subjects with AE and SAE between vaccine and active control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deviation of laboratory evaluation in Phase I</measure>
    <time_frame>7 days after whole schedule dose</time_frame>
    <description>Any deviation from routine laboratory evaluation that probably related to the dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory factor evaluation in Phase I</measure>
    <time_frame>7 days after whole-schedule dose</time_frame>
    <description>The change of interleukin-6 (IL-6) in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity profile of the SARS-CoV-2 protein subunit recombinant vaccine after second dose</measure>
    <time_frame>28 days after second dose</time_frame>
    <description>seropositive rate, seroconversion rate and GMT of IgG antibody and neutralization antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of immunogenicity between 2 and 3 doses</measure>
    <time_frame>28 days after second and third dose</time_frame>
    <description>seropositive rate, seroconversion rate and GMT of IgG antibody and neutralization antibody</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">780</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Adult - Medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 µg dose, adult group (18-59 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult - High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 µg dose, adult group (18-59 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult - Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SARS-CoV-2 inactivated vaccine, adult group (18-59 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly - Medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 µg dose, elderly group (&gt; 60 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly - High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 µg dose, elderly group (&gt; 60 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly - Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SARS-CoV-2 inactivated vaccine, elderly group (&gt; 60 years)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 Protein Subunit Recombinant Vaccine</intervention_name>
    <description>intramuscular injection</description>
    <arm_group_label>Adult - High Dose</arm_group_label>
    <arm_group_label>Adult - Medium dose</arm_group_label>
    <arm_group_label>Elderly - High dose</arm_group_label>
    <arm_group_label>Elderly - Medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 Inactivated Vaccine</intervention_name>
    <description>intramuscular injection</description>
    <arm_group_label>Adult - Control</arm_group_label>
    <arm_group_label>Elderly - Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinically healthy subjects within the following age groups: adults (18-59 years) and&#xD;
             elderly (60 years and above.&#xD;
&#xD;
          2. Subjects have been informed properly regarding the study and signed the informed&#xD;
             consent form.&#xD;
&#xD;
          3. Subjects will commit to comply with the instructions of the investigator and the&#xD;
             schedule of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects concomitantly enrolled or scheduled to be enrolled in another trial.&#xD;
&#xD;
          2. History of vaccination with any investigational product against Covid-19 during or 6&#xD;
             months prior to enrollment.&#xD;
&#xD;
          3. Subjects who have history of Covid-19 in the last 3 months (based on anamnesis or&#xD;
             other examinations).&#xD;
&#xD;
          4. Evolving mild, moderate or severe illness, especially infectious disease or fever&#xD;
             (body temperature ≥37.5℃, measured with infrared thermometer/thermal gun).&#xD;
&#xD;
          5. The result of rapid antigen test is positive.&#xD;
&#xD;
          6. Women who are lactating, pregnant or planning to become pregnant during the study&#xD;
             period (judged by self-report of subjects and urine pregnancy test results).&#xD;
&#xD;
          7. Abnormality hematology and biochemical test results (for phase I).&#xD;
&#xD;
          8. History of asthma, history of allergy to vaccines or vaccine ingredients, and severe&#xD;
             adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema.&#xD;
&#xD;
          9. History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular&#xD;
             injection.&#xD;
&#xD;
         10. Patients with serious chronic diseases (serious cardiovascular diseases, uncontrolled&#xD;
             hypertension and diabetes, liver and kidney diseases, malignant tumors, etc) which&#xD;
             according to the investigator might interfere with the assessment of the trial&#xD;
             objectives.&#xD;
&#xD;
         11. Subjects who have any history of confirmed or suspected immunosuppressive or&#xD;
             immunodeficient state, or received in the previous 4 weeks a treatment likely to alter&#xD;
             the immune response (intravenous immunoglobulins, blood-derived products or long-term&#xD;
             corticosteroid therapy (&gt; 2 weeks)).&#xD;
&#xD;
         12. Subjects who have history of uncontrolled epilepsy or other progressive neurological&#xD;
             disorders, such as Guillain-Barre Syndrome.&#xD;
&#xD;
         13. Subjects receive any vaccination (other than Covid-19 vaccine) within 1 month before&#xD;
             and after Investigational Product (IP) immunization.&#xD;
&#xD;
         14. Subjects plan to move from the study area before the end of study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Rini Sekartini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fakultas Kedokteran Universitas Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rini Mulia Sari, MD</last_name>
    <phone>+6222-2033755</phone>
    <phone_ext>14102</phone_ext>
    <email>rini.mulia@biofarma.co.id</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Prof. Rini Sekartini, MD</last_name>
    <phone>+6221-4894932</phone>
    <email>rsekartini@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fakultas Kedokteran Universitas Indonesia</name>
      <address>
        <city>Jakarta</city>
        <state>Greater Jakarta</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>Prof Rini Sekartini, MD</last_name>
      <phone>+6221-4894932</phone>
      <email>rsekartini@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Bernie Endyarni Medise, MD</last_name>
      <phone>+6221-4894932</phone>
      <email>bernie.medise@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>covid19 vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

